IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.82
−0.52%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.88
From 52W high−37.07%
Volume1.53M
Market cap$317.81M
P/E (TTM)—
P/S (TTM)32.2x
Div yield—
Key dataOct 19, 2026
Open
$3.88
From 52W high
−37.07%
Volume
1.53M
Market cap
$317.81M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
32.7
MomentumView details →
1D Return
−0.52%
YTD Return
+88.54%
SummaryUpdated Jun 1, 2026
Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company founded in 2018 and headquartered in Farmington Hills, Michigan. Originally known as Ocuphire Pharma, Inc., the company went public in 2015 and focuses on developing innovative therapies for patients with refractive and retinal eye disorders. The company operates in the specialized field of ophthalmology, targeting unmet medical needs in eye care through both commercially available products and an active clinical development pipeline.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved Opus Genetics, Inc.’ supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia in adults.3d agoOpus Genetics reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, showing vision improvements.40d ago